 |
66 Companies | 59 Products |
|
|
59 Products | |
344 Diseases | |
313 Trials |  |
11771 News |  |
| «12345678910111213...220221» |
- | LY294002 / Eli Lilly
Journal: Activation of LXRs alleviates neuropathic pain-induced cognitive dysfunction by modulation of microglia polarization and synaptic plasticity via PI3K/AKT pathway. (Pubmed Central) - Jan 31, 2024
LXRs activation alleviates neuropathic pain-induced cognitive impairment by modulating microglia polarization, neuroinflammation, and synaptic plasticity, at least partly via activation of PI3K/AKT signaling in the hippocampus. LXRs may be promising targets for addressing pain-related cognitive deficits.
- | paclitaxel / Generic mfg.
Journal: Curcumin Suppresses M2 Macrophage-derived Paclitaxel Chemoresistance through Inhibition of PI3k-AKT/STAT3 Signaling. (Pubmed Central) - Jan 31, 2024
Our results showed that curcumin reduced the chemoresistance-generating ability of M2 TAMs. The study has revealed a non-cancer cell-autonomous mechanism by which curcumin partly overcomes the chemoresistance of paclitaxel in breast cancer.
- | ezetimibe / Generic mfg.
Journal: Ezetimibe Induces Paraptosis through Niemann-Pick C1-like 1 Inhibition of Mammalian-Target-of-Rapamycin Signaling in Hepatocellular Carcinoma Cells. (Pubmed Central) - Jan 30, 2024
Mechanistically, Ezetimibe induced paraptosis by targeting NPC1L1 to inhibit the PI3K/AKT/mTOR signaling pathway. In conclusion, our study highlights the potential of Ezetimibe as an anticancer agent by triggering paraptosis in HCC cells.
- | Journal: Ginsenoside Rg5 induces NSCLC cell apoptosis and autophagy through PI3K/Akt/mTOR signaling pathway. (Pubmed Central) - Jan 30, 2024
In conclusion, our study highlights the potential of Ezetimibe as an anticancer agent by triggering paraptosis in HCC cells. Rg5 induced autophagy and caspase-dependent apoptosis in NSCLC cells by inhibiting the PI3K/Akt/mTOR signaling pathway, suggesting that Rg5 might become a promising and novel anti-tumor agent for the clinical treatment of NSCLC patients.
- | taselisib (GDC-0032) / Roche
Journal, Heterogeneity: Transcriptome data-based status of PI3K/AKT/mTOR pathway indicates heterogeneity and immune modulation in patients with pancreatic ductal adenocarcinoma. (Pubmed Central) - Jan 30, 2024
Rg5 induced autophagy and caspase-dependent apoptosis in NSCLC cells by inhibiting the PI3K/Akt/mTOR signaling pathway, suggesting that Rg5 might become a promising and novel anti-tumor agent for the clinical treatment of NSCLC patients. These findings suggest that targeting the PI3K/AKT/mTOR pathway may have therapeutic potential in PDAC, and distinct pathway states, immune modulation and tumor microenvironments have prognostic value.
- | Piqray (alpelisib) / Novartis, ICA-1 / University of South Florida
Journal: Dual inhibition of atypical PKC signaling and PI3K/Akt signaling dysregulates c-Myc to induce apoptosis in clear cell Renal Cell Carcinoma. (Pubmed Central) - Jan 30, 2024
Therefore, implementing a combination of Alpelisib and a PKC-? inhibitor is an effective approach to reducing cell proliferation, and invasion that eventually induces apoptosis and may be considered as a potential therapeutic option in ccRCC.
- | Journal: OTUD3 suppresses the mTORC1 signaling by deubiquitinating KPTN. (Pubmed Central) - Jan 30, 2024
We propose a novel mechanism involving KPTN-mediated regulation of the mTORC1 signaling pathway, offering fresh insights into the occurrence and progression of tumor diseases driven by related genes. This may inspire new approaches for drug screening and cancer treatment, potentially guiding future therapies for relevant tumors.
- | pirfenidone / Generic mfg.
Journal, Machine learning: Logic-based mechanistic machine learning on high-content images reveals how drugs differentially regulate cardiac fibroblasts. (Pubmed Central) - Jan 28, 2024
The model predicted how pirfenidone and Src inhibitor WH-4-023 reduce actin filament assembly and actin-myosin stress fiber formation, respectively...In this study, we establish a modeling approach combining the strengths of logic-based network models and regularized regression models. We apply this approach to predict mechanisms that mediate the differential effects of drugs on fibroblasts, revealing Src inhibition acting via PI3K as a potential therapy for cardiac fibrosis.
- | Mekinist (trametinib) / Novartis, BeiGene, Aliqopa (copanlisib) / Bayer
Journal: Lung Fibroblasts Take up Breast Cancer Cell-derived Extracellular Vesicles Partially Through MEK2-dependent Macropinocytosis. (Pubmed Central) - Jan 27, 2024
Through a phenotypic screen, we found that MEK inhibitor Trametinib suppressed EV uptake and macropinocytosis in lung fibroblasts, and that EV uptake is mediated by MEK2 in these cells. Our results suggest that MEK2 inhibition could serve as a strategy to block cancer EV uptake by lung fibroblasts.
- | LY294002 / Eli Lilly
Preclinical, Journal: Furanocoumarins as Enhancers of Antitumor Potential of Sorafenib and LY294002 toward Human Glioma Cells In Vitro. (Pubmed Central) - Jan 27, 2024
In both anaplastic astrocytoma and glioblastoma, imperatorin was the most effective in induction apoptosis. Furthermore, the usage of imperatorin, alone and in combination with sorafenib or LY294002, decreased the migratory potential of MOGGCCM and T98G cells.
- || Retrospective data, Review, Journal: Efficacy and Safety of Phosphatidylinositol 3-kinase Inhibitors for Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials. (Pubmed Central) - Jan 26, 2024
PI3K inhibitors had better efficacy than the present standard of concern for patients with breast cancer, especially among patients with PIK3CA mutations. Hence, clinicians and oncologists can provide this drug for the target population with extra caution for diabetes patients.
- | bleomycin / Generic mfg.
Journal, IO biomarker: MicroRNA?203a?3p improves bleomycin and pingyangmycin sensitivity by inactivating the PI3K/AKT pathway in hemangioma. (Pubmed Central) - Jan 26, 2024
Of note, 740 Y-P weakened the effect of miR-203a-3p overexpression on the aforementioned cellular characteristics. The present study demonstrated that miR-203a-3p improved the sensitivity of cells to bleomycin and pingyangmycin treatment by inhibiting PI3K/AKT signaling in hemangioma.
- | LY294002 / Eli Lilly
Journal: Tumor-suppressive action of miR-30a-5p in lung adenocarcinoma correlates with ABL2 inhibition and PI3K/AKT pathway inactivation. (Pubmed Central) - Jan 26, 2024
The present study demonstrated that miR-203a-3p improved the sensitivity of cells to bleomycin and pingyangmycin treatment by inhibiting PI3K/AKT signaling in hemangioma. This study underscores the inhibitory role of miR-30a-5p in LUAD through the ABL2/PI3K/AKT axis, which may be a viable target for LUAD treatment.
- | Piqray (alpelisib) / Novartis, MK-8776 / Merck (MSD)
Journal: Integrative modeling uncovers p21-driven drug resistance and prioritizes therapies for PIK3CA-mutant breast cancer. (Pubmed Central) - Jan 25, 2024
Together, our integrated studies uncover hidden molecular mediators causing resistance to PI3K? inhibition and provide a framework to prioritize combination therapies for PI3K-mutant breast cancer.
- | Itari (linperlisib) / Shanghai YingLi Pharma
New P2 trial: Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia (clinicaltrials.gov) - Jan 25, 2024
P2, N=41, Recruiting, Sponsor: Institute of Hematology & Blood Diseases Hospital, China
- | Journal: Targeted Inhibition of the PI3K/Akt/mTOR Signaling Axis: Potential for Sarcoma Therapy. (Pubmed Central) - Jan 24, 2024
While there are still challenges to be addressed, the preclinical and clinical evidence suggests that these inhibitors may significantly improve patient outcomes. Further research is needed to understand the potential of these inhibitors as sarcoma therapeutics and to continue developing more selective and effective agents to meet the clinical needs of sarcoma patients.
- || Review, Journal: A comprehensive review of small molecules targeting PI3K pathway: Exploring the structural development for the treatment of breast cancer. (Pubmed Central) - Jan 24, 2024
These drugs are used for the treatment of breast cancer but still have various side effects with their high cost. Therefore, the primary goal of this review is to include all current advances in the development of anticancer medicines that target PI3K over-activation in the treatment of breast cancer.
- | CBT-1 (tetrandrine) / CBA Pharma
Journal: Novel sulfonyl-substituted tetrandrine derivatives for colon cancer treatment by inducing mitochondrial apoptosis and inhibiting PI3K/AKT/mTOR pathway. (Pubmed Central) - Jan 24, 2024
Ultimately, compound 3c dramatically suppressed tumor growth in the CT26 xenograft tumor model, without noticeable visceral toxicity detected in the high-dose group. In summary, compound 3c might present new insights for designing new PI3K inhibitors and be a potential candidate for colon cancer treatment.
- | LY294002 / Eli Lilly
Journal: miR-30a-5p targets ITGA6 to inhibit oral squamous cell carcinoma progression. (Pubmed Central) - Jan 24, 2024
In summary, compound 3c might present new insights for designing new PI3K inhibitors and be a potential candidate for colon cancer treatment. Taken together, miR-30a-5p prevents OSCC progression by inhibiting PI3K/AKT pathway through inhibition of ITGA6 expression.
- | Journal: Prediction of Novel Natural Small Molecules From Schinus molle as an Inhibitor of PI3K Protein Target in Cancer Cells Using In Silico Screening. (Pubmed Central) - Jan 23, 2024
Beta-spathulene and kaempferol demonstrated significant affinity for PI3K and favorable attributes concerning drug-likeness, pharmacokinetics, and bioavailability. Conclusion While our computational investigation lays a promising foundation, it is essential to emphasize that further experimental studies, including in vitro and in vivo experiments, are imperative to validate the action of these lead compounds.
- Piqray (alpelisib) / Novartis, RLY-2608 / Relay Therap, inavolisib (GDC-0077) / Roche
Allosteric PI3K-alpha inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations () - Jan 22, 2024 - Abstract #YIR2024YIR_142;
Genomic alterations within the PI3K pathway represent a major mode of resistance and identify a novel class of secondary PIK3CA resistance mutations that can be overcome by an allosteric PI3Ka inhibitor. Together, these findings provide insights to guide strategies to overcome resistance in PIK3CA-mutated cancers.
- | Journal: Baicalin?-?2- ethoxyethyl ester alleviates renal fibrosis by inhibiting PI3K/AKT/NF-?B signaling pathway. (Pubmed Central) - Jan 21, 2024
The western blotting analysis confirmed that BAE could inhibit the expression of ?-SMA, TGF-?1, p-PI3K, p-AKT, p-I?B?, and NF-?B p65. We found that BAE can inhibit the inflammatory reaction and promote the degradation of the extracellular matrix by inhibiting the activation of the PI3K/AKT/NF-?B pathway, thus alleviating the symptoms of renal fibrosis in 5/6Nx rats, which revealed BAE was a potential compound to relieve renal fibrosis effect.
- Digoxigenin activates autophagy in HCC by regulating the PI3K/Akt/mTOR pathway () - Jan 20, 2024 - Abstract #APASL2024APASL_2509;
In summary, we identify DIG as a potential treatment option for HCC because it inhibits the PI3K/AKT/mTOR signaling pathway, which causes HCC cells to undergo autophagy. By employing phenotypic screening, this research contributes to accelerated drug discovery and the development of new therapies to address the underlying mechanisms associated with liver cancer.
- | XL388 / Exelixis
Journal: Virtual docking screening and quantitative structure-activity relationship studies to explore AKT and PI3K inhibitors acting on mTOR in cancers by theoretical biology and medical modeling. (Pubmed Central) - Jan 19, 2024
The best predicted AKT and PI3K inhibitor pIC50 activities were 9.36-9.95 and 9.23-9.87 respectively. After docking and several comparisons, the inhibitors with better predictions showed better affinity and interaction with mTOR compared to AZ8055 and XL388, so we have found that 2 AKT inhibitors and 9 mTOR inhibitors met the Lipinski and Veber criteria and could be future drugs.
- | Journal, Synthetic lethality: Methylation of NRIP3 is a synthetic lethal marker for combined PI3K and ATR/ATM inhibitors in CRC. (Pubmed Central) - Jan 18, 2024
NRIP3 is a potential tumor suppressor. NRIP3 methylation is a potential synthetic lethal marker for combined PI3K and ATR/ATM inhibitors.
- | cisplatin / Generic mfg., nicorandil / Generic mfg.
Preclinical, Journal, IO biomarker: Nicorandil attenuates cisplatin-induced acute kidney injury in rats via activation of PI3K/AKT/mTOR signaling cascade and inhibition of autophagy. (Pubmed Central) - Jan 18, 2024
Our study showed the nephroprotective effects of nicorandil in cisplatin-induced AKI in rats via activation of PI3K/AKT/mTOR signaling cascade, inhibition of autophagy, anti-inflammatory, anti-apoptotic, anti-oxidant activities. Thus, nicorandil could represent a promising renoprotective agent in cancer patients treated with cisplatin.
- | Preclinical, Journal: Liensinine alleviates mouse intestinal injury induced by sepsis through inhibition of oxidative stress, inflammation, and cell apoptosis. (Pubmed Central) - Jan 18, 2024
And then it reduced the excessive apoptosis of intestinal cells. This study provides valuable insights for sepsis prevention and treatment, offering a potential therapeutic candidate to protect against intestinal injury and regulate the inflammatory response in sepsis.
- | Journal, IO biomarker: MiR-29a mediates the apoptotic effects of TNF-? on endothelial cells through inhibiting PI3K/AKT/BCL-2 axis. (Pubmed Central) - Jan 18, 2024
Mediating the inflammation-driven endothelial cell apoptosis is an important biology mechanism by which miR-29a promotes atherosclerosis and its complications. MiR-29a will be a potential diagnostic and therapeutic target for atherosclerotic cardiovascular diseases; it is worthwhile to further study.
- Piqray (alpelisib) / Novartis, defactinib (VS-6063) / Verastem
The Role And Mechanism Of KMT2D To Modulate PI3Ka Inhibitor Response In Cervical Cancer Identified By CRISPR/Cas9 Genome-Wide Screening (Poster area) - Jan 18, 2024 - Abstract #ESGO2024ESGO_797;
This study provides insights for clinical trials, emphasizing the potential of KMT2D as a predictive marker for PI3K? inhibitors in cervical cancer treatment.
- Piqray (alpelisib) / Novartis
Alpelisib For PIK3CA-Mutated Advanced Gynecological Cancers: First Clues Of Clinical Activity (Poster area) - Jan 18, 2024 - Abstract #ESGO2024ESGO_352;
Conclusion Alpelisib represents an active treatment option in patients with recurrent gynecological cancers harboring a PIK3CA mutation. These findings support the need of biomarker-driven randomized trials of PI3K inhibitors in gynecological cancers.
- Aliqopa (copanlisib) / Bayer
Trial completion date, Trial primary completion date, Combination therapy: Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations (clinicaltrials.gov) - Jan 17, 2024
P2, N=7, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
These findings support the need of biomarker-driven randomized trials of PI3K inhibitors in gynecological cancers. Trial completion date: Oct 2026 --> Aug 2024 | Trial primary completion date: Oct 2026 --> Aug 2024
- | LY294002 / Eli Lilly, PD98059 / Wayne State University
Journal: NCAM mimetic peptide P2 synergizes with bone marrow mesenchymal stem cells in promoting functional recovery after stroke. (Pubmed Central) - Jan 17, 2024
Treatment with LY294002 (PI3K inhibitor) and PD98059 (ERK inhibitor) decreased the neuroprotective effects of combined P2 and BMSC therapy in MCAO rats. Collectively, P2 is neuroprotective while P2 and BMSCs work synergistically to improve functional outcomes after ischemic stroke, which may be attributed to mechanisms involving enhanced BMSC proliferation and neurotrophic factor release, anti-apoptosis, and PI3K/AKT and ERK pathways activation.
- | doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg.
Journal: Suppression of malignant melanoma by knocking down growth differentiation factor-15 via inhibiting PTEN/PI3K/AKT signaling pathway. (Pubmed Central) - Jan 17, 2024
GDF15 regulated the cell proliferation, apoptosis, migration, invasion, and EMT process of M14 and M21 cell lines through targeting PTEN/PI3K/AKT signaling pathway. This research provides a novel prevention and treatment strategy for melanoma.
- || Review, Journal: Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects. (Pubmed Central) - Jan 17, 2024
This article provides a comprehensive review of the structure and biological functions, and clinical status of PI3K inhibitors, with a specific emphasis on the development strategies and structure-activity relationships of dual-target PI3K inhibitors. The findings offer valuable insights and future directions for the development of highly promising dual-target drugs targeting PI3K.
- | Calsed (amrubicin) / Sumitomo Pharma, BMS
Journal: Amrubicin encapsulated PLGA NPs inhibits the PI3K/AKT signaling pathway by activating PTEN and inducing apoptosis in TMZ-resistant Glioma. (Pubmed Central) - Jan 17, 2024
These findings indicate that AMR-PLGA-NPs can be an effective and flexible nanoplatform for treating GBM while addressing drug resistance issues. Overall, the study demonstrates the potential of AMR-PLGA-NPs as a stable and safe treatment option for GBM, addressing the major issue of drug resistance in these types of tumors. .
- | LY294002 / Eli Lilly
Journal: Modified Guo-Min decoction ameliorates PM2.5-induced lung injury by inhibition of PI3K-AKT and MAPK signaling pathways. (Pubmed Central) - Jan 17, 2024
The results of this study support and provide scientific evidence for the clinical application of MGMD on PM2.5-induced lung injury. Pre-treatment, sync-treatment, and post-treatment is the highlight of this study.
- | LY294002 / Eli Lilly
Journal: MiR-150-5p contributes to unexplained recurrent spontaneous abortion by targeting VEGFA and downregulating the PI3K/AKT/mTOR signaling pathway. (Pubmed Central) - Jan 17, 2024
Pre-treatment, sync-treatment, and post-treatment is the highlight of this study. Overall, these findings imply that miR-150-5p is among the key factors that regulate the pathogenesis of URSA.
- | Journal: Low-dose Lipopolysaccharide Alleviates Spinal Cord Injury-induced Neuronal Inflammation by Inhibiting microRNA-429-mediated Suppression of PI3K/AKT/Nrf2 Signaling. (Pubmed Central) - Jan 17, 2024
Inhibition of miR-429 blocked low-dose LPS-mediated oxidative stress and inflammation via activation of the PI3K/AKT/Nrf2 pathway. Overall, low-dose LPS was found to alleviate SCI-induced neuronal oxidative stress and inflammatory response by down-regulating miR-429 to activate the PI3K/AKT/Nrf2 pathway.
- | fenofibrate / Generic mfg.
Journal: Fenofibrate suppresses the progression of hepatoma by downregulating osteopontin through inhibiting the PI3K/AKT/Twist pathway. (Pubmed Central) - Jan 17, 2024
Furthermore, the inhibitory effect of fenofibrate on the PI3K/AKT/Twist pathway in Hep3B cells and Hep3B xenograft model was abrogated by OPN overexpression. Collectively, fenofibrate suppressed progression of hepatoma downregulating OPN through inhibiting the PI3K/AKT/Twist pathway.
- | Epidaza (chidamide) / Chipscreen, Meiji Seika, Eisai, HUYA Bioscience
Journal: HDAC inhibitors target IRS4 to enhance anti?AR therapy in AR?positive triple?negative breast cancer. (Pubmed Central) - Jan 16, 2024
In conclusion, the results of the present study revealed that combination treatment with Enz and Chid can upregulate IRS4, which results in the blocking of KRAS signalling and suppression of tumour growth. It may be hypothesised that the expression levels of IRS4 could be used as a biomarker for screening patients with AR?positive TNBC using Enz and Chid combination therapy.
- | Journal: Chemical Proteomics and Morphological Profiling Revealing MYDGF as a Target for Synthetic Anticancer Macromolecules. (Pubmed Central) - Jan 16, 2024
Through morphological profiling, we also identify similarities in phenotypic effects of the functionalized polycarbonates with topoisomerase I inhibitors, MDM2 inhibitors, and phosphatidylinositol 3kinase inhibitors against cancer cells, suggesting a common mechanism through the PIK3/AKT pathway leading to apoptosis. These findings present the first macromolecular compound targeting MYDGF and may serve as an example for MYDGF modulation as a potential new target for macromolecular chemotherapeutic development.
- | LY294002 / Eli Lilly
Preclinical, Journal, IO biomarker: Chuanzhitongluo inhibits neuronal apoptosis in mice with acute ischemic stroke by regulating the PI3K/AKT signaling pathway. (Pubmed Central) - Jan 16, 2024
These findings present the first macromolecular compound targeting MYDGF and may serve as an example for MYDGF modulation as a potential new target for macromolecular chemotherapeutic development. These findings imply that CZTL's ability to inhibit neuronal apoptosis may be linked to the activation of AIS's PI3K/AKT signaling pathway.
- | Journal: Study on the mechanism of action of Saposhnikovia divaricata and its key phytochemical on rheumatoid arthritis based on network pharmacology and bioinformatics. (Pubmed Central) - Jan 15, 2024
Our findings provide insights into the therapeutic effects of SD on RA, successfully predicting the effective ingredients and potential targets, which could suggest a novel theoretical basis for further exploration of its molecular mechanisms. It also revealed that Prangenidin inhibited viability, migration, invasion, cytokine, and MMPs expression, and induced apoptosis in RA FLSs via the PI3K/AKT pathway.
- | Journal: Enhanced VEGF secretion and blood-brain barrier disruption: Radiation-mediated inhibition of astrocyte autophagy via PI3K-AKT pathway activation. (Pubmed Central) - Jan 15, 2024
In conclusion, our study suggests that radiation can inhibit autophagy and promote VEGF oversecretion by upregulating the PI3K-AKT pathway in astrocytes. Blocking the PI3K pathway can alleviate both of these effects, thereby mitigating damage to the BBB in patients undergoing radiation treatment.
- | Journal: Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids. (Pubmed Central) - Jan 15, 2024
The combination of MAPK and PI3K inhibitors reversed Braf oncogene-promoted cell dedifferentiation while restoring thyroid follicle organization and function in vitro. Our results demonstrate that pluripotent stem cells-derived thyroid cancer organoids can mimic tumor development and features while providing an efficient tool for testing novel targeted therapies.
- | Venclexta (venetoclax) / Roche, AbbVie, Ukoniq (umbralisib) / TG Therap, Briumvi (ublituximab-xiiy) / TG Therap, Neuraxpharm
Journal: Response-Adapted, Time-Limited Venetoclax, Umbralisib and Ublituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia. (Pubmed Central) - Jan 15, 2024
P1/2
Time-limited venetoclax and U2 is safe and highly effective combination therapy for relapsed/refractory CLL patient including those who have been previously treated with covalent BTK inhibitors. This trial was registered on ClinicalTrials.gov under identifier: NCT03379051.
- | Victoza (liraglutide) / Novo Nordisk
Journal: Liraglutide attenuates obese-associated breast cancer cell proliferation via inhibiting PI3K/Akt/mTOR signaling pathway. (Pubmed Central) - Jan 15, 2024
Our results reveal that transfection of AMPK/SIRT-1 genes did not affect the beneficial role of LGT in the expression of adipokines in ADSCs. In conclusion, LGT elicits anti-proliferative, apoptotic, and anti-migratory effects on BC cells in obese conditions by suppressing the activity of survival pathways; however, this effect is independent of the AMPK/SIRT1 pathway in ADSCs or AMPK in BC cells.
- | Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Journal: Essential Oil of Matricaria chamomilla Alleviate Psoriatic-Like Skin Inflammation by Inhibiting PI3K/Akt/mTOR and p38MAPK Signaling Pathway. (Pubmed Central) - Jan 15, 2024
At the same time, we prepared imiquimod-induced psoriatic-like skin inflammation in mice to investigate thoroughly the potential inhibition functions of MCEO on psoriatic skin injury and inflammation...MCEO ameliorated skin injury in IMQ-induced psoriatic-like skin inflammation of mice by downregulating the levels of inflammatory cytokines but not IL-17A. Thus, anti-inflammatory plant drugs with different targets with combined applications were a potential therapeutic strategy in psoriasis.
- | Journal: Nanoemulsion potentiates the anti-cancer activity of Myricetin by effective inhibition of PI3K/AKT/mTOR pathway in triple-negative breast cancer cells. (Pubmed Central) - Jan 14, 2024
Mechanistic investigation revealed that nanoemulsion augmented the anti-cancer efficacy of Myricetin, most likely by inhibiting the PI3K/AKT/mTOR pathway, eventually leading to enhanced cell death in TNBC cells. The study provides substantial experimental evidence to support the notion that the Myr-NE formulation has the potential to be an effective therapeutic drug for TNBC treatment.
- | Preclinical, Journal: Exploration of anti?osteosarcoma activity of asiatic acid based on network pharmacology and in (Pubmed Central) - Jan 12, 2024
In addition, asiatic acid decreased the levels of phosphorylated (p?)PI3K/PI3K and p?AKT/AKT, increased reactive oxygen species (ROS) and upregulated the levels of p?ERK1/2/ERK1/2, p?p38/p38 and p?JNK/JNK in osteosarcoma cells. These results demonstrated that asiatic acid inhibited osteosarcoma cells proliferation by inhibiting PI3K/AKT and activating ROS/MAPK signaling pathways, suggesting asiatic acid is a potential agent against osteosarcoma.